KPTI Stock Analysis: Buy, Sell, or Hold?
KPTI - Karyopharm Therapeutics Inc.
$8.90
0.05 (0.56%)
▲
5d:
+0.56%
30d:
+3.97%
90d:
-0.45%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Distribution
KPTI is up 6.5% this week, but smart money is buying puts. Top strike: $10 2026-06-18 with 8 OI. Put ratio: 100% View Scanner →
Strength: 8.2/10
Get Alerted When KPTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KPTI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KPTI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KPTI is currently trading at $8.90, which is considered slightly high relative to its 30-day fair value range of $7.89 to $9.23.
Technical Outlook: Technically, KPTI is in a uptrend. Immediate support is located at $8.25, while resistance sits at $10.23.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.17 (+47.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KPTI is in a uptrend. Immediate support is located at $8.25, while resistance sits at $10.23.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.17 (+47.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.89 -
$9.23
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 47.9% below Wall St target ($13.17)
Trading Range Analysis
30-Day Trading Range
$7.89 -
$9.23
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.25
Resistance Level
$10.23
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.04
Wall Street Target
$13.17
(+47.9%)
Revenue Growth (YoY)
11.6%
Profit Margin
-134.2%
Share & Embed Analysis
Last updated: May 14, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Reshma Rangwala
SELL
449 shares
2026-04-21
Kristin Abate
SELL
50 shares
2026-01-28
Kristin Abate
SELL
265 shares
2026-01-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 54 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 58 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 59 HOLD |
